M30 Apoptosense in NASH Clinical Trials
We are proud to announce that the M30 Apoptosense® ELISA, for use in NASH clinical trials, will be discussed on an Xtalks webinar!
NAFLD is a medical condition characterized by the build-up of fat in the liver and has a spectrum that ranges from steatosis and NASH to fibrotic NASH and cirrhosis. The incidence of NAFLD worldwide is 20-35%, and there are currently no approved drug therapies for NAFLD or NASH.
As biopsy is still the “gold standard” for diagnosis of NASH, non-invasive biomarkers are urgently needed to identify patients and determine their response to novel therapeutic agents.
Markers of hepatic cell death such as keratin 18 (K18) and its caspase-cleaved fragment, ccK18, have been suggested as endpoints for early clinical drug trials. The M30 Apoptosense® ELISA is a specific and reliable tool to measure the concentration of ccK18 fragments. Celerion has validated the M30 Apoptosense® ELISA for use as a secondary endpoint in NASH clinical trials.
Webinar Information
• Monday, October 22, 2018
• 11am EDT (NA)
• 4pm BST (UK)
• 5pm CEST (EU-Central)
• Duration: 60 min
This webinar is sponsored by Diapharma Group, Inc